Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) confirmed it will announce results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis in the second half of January 2026.

The company said the timing prompted cancellation of all previously planned conference attendance, including its presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026.

News Market Reaction – CRVS

-7.24%

16 alerts

-7.24% News Effect

-17.4% Trough in 25 hr 7 min

-$43M Valuation Impact

$547M Market Cap

1.0x Rel. Volume

On the day this news was published, CRVS declined 7.24%, reflecting a notable negative market reaction. Argus tracked a trough of -17.4% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $43M from the company's valuation, bringing the market cap to $547M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cohort 4 timing: Second half of January 2026 Cash balance: $65.7M Q3 2025 R&D expense: $8.5M +5 more

8 metrics

Cohort 4 timing Second half of January 2026 Soquelitinib Phase 1 atopic dermatitis cohort 4 results

Cash balance $65.7M Cash, cash equivalents and marketable securities as of Sept 30, 2025 (Q3 2025 10-Q)

Q3 2025 R&D expense $8.5M Research and development expense for Q3 2025 vs $5.2M year-ago

Q3 2025 net loss $10.2M Net loss for the quarter ended Sept 30, 2025

Phase 1/1b cohort size 36 patients Soquelitinib 200 mg BID T cell lymphoma cohort (Phase 1/1b)

Median PFS 6.2 months Phase 1/1b soquelitinib T cell lymphoma trial (200 mg BID cohort)

Median OS 28.1 months Phase 1/1b soquelitinib T cell lymphoma trial (200 mg BID cohort)

ATM program size $100 million At-the-market program disclosed in Q3 2025 10-Q, no sales to date

Market Reality Check

Price: $18.26 Vol: Volume 899,504 is below t...

low vol

$18.26 Last Close

Volume Volume 899,504 is below the 20-day average of 1,677,727 (relative volume 0.54). low

Technical Shares at $7.32 are trading above the 200-day moving average of $5.50 and 23.75% below the 52-week high.

Peers on Argus

CRVS is down 4.94% with below-average volume. Key biotech peers like ALMS (-8.34...

CRVS is down 4.94% with below-average volume. Key biotech peers like ALMS (-8.34%), REPL (-8.9%), and PRTA (-3.77%) are also weaker, but the momentum scanner shows no coordinated sector move, suggesting today’s trading is more stock-specific.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Clinical data update	Positive	-2.8%	Final Phase 1/1b soquelitinib lymphoma data presented with encouraging efficacy and safety.
Nov 04	Earnings and update	Positive	-0.5%	Q3 2025 results with cash runway into Q4 2026 and pipeline milestones outlined.
Nov 03	Conference presentation	Positive	-4.5%	Announcement of final Phase 1/1b lymphoma data oral presentation at ASH.
Oct 31	Investor conference	Positive	+3.6%	Participation and fireside chat at Guggenheim Healthcare Innovation Conference.
Oct 28	Earnings date notice	Neutral	-3.4%	Scheduling of Q3 2025 business update and earnings call details.

Pattern Detected

Recent clinical and corporate updates, even when positive, have often seen negative short-term price reactions, indicating a tendency for divergence between news tone and immediate trading.

Recent Company History

Over the last few months, Corvus has focused on advancing soquelitinib in both T cell lymphoma and atopic dermatitis. Final Phase 1/1b lymphoma data were presented at ASH on Dec 8, 2025, while prior updates flagged that atopic dermatitis cohort 4 data were expected in Jan 2026. Financially, Q3 2025 results highlighted $65.7M in cash and continued R&D spend. Today’s announcement mainly narrows timing for the atopic dermatitis Phase 1 cohort 4 readout and cancels conference appearances, fitting into this ongoing clinical execution narrative.

Market Pulse Summary

The stock moved -7.2% in the session following this news. A negative reaction despite the largely ti...

Analysis

The stock moved -7.2% in the session following this news. A negative reaction despite the largely timing-focused announcement would fit prior patterns where positive or neutral updates were followed by weakness. The company previously reported $65.7M in cash as of Q3 2025 alongside continued losses and an at-the-market program, factors that can amplify downside when uncertainty about upcoming data exists. Traders may have reassessed risk around the atopic dermatitis Phase 1 cohort 4 readout slated for the second half of January 2026 and the cancellation of conference appearances.

Key Terms

randomized, blinded, placebo-controlled, phase 1, +1 more

5 terms

randomized medical

"randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

blinded medical

"randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib"

Blinded describes a setup in a clinical study where one or more parties — such as patients, doctors, or people analyzing results — do not know which treatment was given, preventing their expectations from influencing outcomes. For investors, blinding matters because it makes trial results more reliable and reduces the risk that positive or negative findings are driven by bias rather than the treatment itself, much like a referee making calls without knowing which team is favored.

placebo-controlled medical

"randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

phase 1 medical

"placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

atopic dermatitis medical

"clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis in the second half of January 2026. Given the proximity to our upcoming data, we are cancelling all previously planned conference attendances, including our presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12th.

About Corvus Pharmaceuticals 
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is now in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements related to the timing of the announcement of the results from cohort 4 of the Company’s Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

When will Corvus (CRVS) announce cohort 4 results for soquelitinib?

Corvus expects to announce cohort 4 results in the second half of January 2026.

Why did Corvus (CRVS) cancel its J.P. Morgan 2026 Healthcare Conference presentation?

Corvus cancelled the presentation due to the proximity of the cohort 4 data release in January 2026.

What trial is Corvus (CRVS) reporting results for in January 2026?

Results are from the randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis.

Will Corvus (CRVS) still attend other investor conferences in January 2026?

Corvus cancelled all previously planned conference attendances ahead of the planned data announcement.

What should investors watch for in the Corvus (CRVS) January 2026 data release?

Investors should look for the cohort 4 safety and efficacy readouts from the Phase 1 placebo-controlled study.